DK1007092T3 - En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb - Google Patents

En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb

Info

Publication number
DK1007092T3
DK1007092T3 DK98944501T DK98944501T DK1007092T3 DK 1007092 T3 DK1007092 T3 DK 1007092T3 DK 98944501 T DK98944501 T DK 98944501T DK 98944501 T DK98944501 T DK 98944501T DK 1007092 T3 DK1007092 T3 DK 1007092T3
Authority
DK
Denmark
Prior art keywords
alternative pathway
complement activation
activation via
inhibiting complement
inhibiting
Prior art date
Application number
DK98944501T
Other languages
English (en)
Inventor
Kurt R Brunden
Rekha Gupta-Bansal
James B Parent
Original Assignee
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc filed Critical Amgen Fremont Inc
Application granted granted Critical
Publication of DK1007092T3 publication Critical patent/DK1007092T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Cereal-Derived Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • External Artificial Organs (AREA)
DK98944501T 1997-08-26 1998-08-24 En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb DK1007092T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26

Publications (1)

Publication Number Publication Date
DK1007092T3 true DK1007092T3 (da) 2006-10-02

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98944501T DK1007092T3 (da) 1997-08-26 1998-08-24 En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb

Country Status (13)

Country Link
US (3) US6333034B1 (da)
EP (1) EP1007092B1 (da)
JP (1) JP2001513576A (da)
AT (1) ATE335511T1 (da)
AU (1) AU756490B2 (da)
CA (1) CA2302317A1 (da)
DE (1) DE69835524T2 (da)
DK (1) DK1007092T3 (da)
ES (1) ES2270530T3 (da)
NO (1) NO20000935L (da)
NZ (1) NZ503033A (da)
PT (1) PT1007092E (da)
WO (1) WO1999010009A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
CA2454562A1 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
ES2432112T3 (es) * 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
US20080050391A1 (en) * 2004-03-30 2008-02-28 Lazarus Alan H Method for Treating Autoimmune Diseases With Antibodies
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2610340C (en) * 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
EP3299027A1 (en) * 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
CN101932337A (zh) * 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US8435512B2 (en) 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110160636A1 (en) * 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
US20110262456A1 (en) * 2008-11-14 2011-10-27 Rekha Bansal Method of treating ischemia reperfusion injury
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN103068396B (zh) * 2010-03-02 2016-07-06 诺沃姆德治疗公司 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途
AU2011224224B2 (en) * 2010-03-10 2015-07-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
US9243060B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized anti-factor C3b antibodies and uses thereof
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
EP2904014A4 (en) 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
AU2191795A (en) * 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation

Also Published As

Publication number Publication date
ES2270530T3 (es) 2007-04-01
US20030198636A1 (en) 2003-10-23
EP1007092A1 (en) 2000-06-14
NO20000935D0 (no) 2000-02-25
AU756490B2 (en) 2003-01-16
PT1007092E (pt) 2006-12-29
US6333034B1 (en) 2001-12-25
WO1999010009A1 (en) 1999-03-04
EP1007092B1 (en) 2006-08-09
JP2001513576A (ja) 2001-09-04
CA2302317A1 (en) 1999-03-04
DE69835524T2 (de) 2007-04-05
US20020015701A1 (en) 2002-02-07
NZ503033A (en) 2003-01-31
AU9203398A (en) 1999-03-16
NO20000935L (no) 2000-04-18
DE69835524D1 (de) 2006-09-21
ATE335511T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
DK1007092T3 (da) En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb
IS5447A (is) Ferli til að smíða 1,3-díól
DK0960109T3 (da) Fremgangsmåde til fremstilling af tolterodin
BG102474A (en) (-)-cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidine-1-yletoxi)phenyl)-5,6,7 ,8-tetrahydronaphthalen-2-ol-d-tartarate
NO975387D0 (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
DK0715631T3 (da) Fremgangsmåde til fremstilling af N-amino-1-hydroxyalkyliden-1,1-diphosphonsyrer
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
DK0858440T3 (da) Fremgangsmåde til fremstilling af 1,1,1,3,3-pentafluorpropan
DK0937055T3 (da) Fremgangsmåde til fremstilling af d,I-alfa-tocopherol
ATE201203T1 (de) Chirale methylphenyloxazolidinone
TR199601005A2 (tr) Uzun zincirli, dallanmis poliolefinlerin üretimi icin yöntem.
DK0885191T3 (da) Opspaltning af threo-methylphenidat
WO2000024920A3 (de) VERFAHREN ZUR GEWINNUNG VON η-DECALACTON
IS4190A (is) Hliðstæð aðferð til framleiðslu á 1,5 bensódíasepín afleiðum
MX9603277A (es) Metodo para moldear una camara de seccion decreciente.
ATE237568T1 (de) Neue substanzbibliothek und damit hergestellte supramolekulare komplexe
DK0805806T3 (da) Fremgangsmåde til fremstilling af 4,10-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxotax-11-en-13alpha-
BG103649A (en) Method for the preparation of eprosartan
AU1160700A (en) Ppar gamma ligands
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
BG103650A (en) Method for the preparation of eprosartan
DK1086114T3 (da) Morfin-6-glucuronidsyntese
DK0975569T3 (da) Fremgangsmåde til hydroxylering af 1,4-dichlorbenzen